Clinical Trial

Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, multicenter, single-arm, open-label study. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with mFOLFIRINOX/GX for postoperative adjuvant treatment of pancreatic cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-24.
Trial Details
NCT Number NCT06389760
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Pancreatic Cancer
Enrollment 57 participants
Start Date 2023-10-18
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-31